The New England Journal of MedicineAntidepressant Augmentation vs. Switch in Treatment-Resistant Geriatric Depression

Aripiprazole supplementation of existing antidepressants in older adults with treatment-resistant depression significantly improved wellbeing over 10 weeks compared to switching to bupropion, and it was also associated with a numerically higher incidence of remission. Changes in wellbeing and the occurrence of remission with lithium augmentation or a switch to nortriptyline were comparable among patients in whom augmentation or a switch to bupropion failed.